Quick Answer
Acrivon Therapeutics, Inc. reported Net Income Loss of -$77.91 million for the year ending 2025.
- Acrivon Therapeutics, Inc. showed an increase of +3.3% in Net Income Loss from 2024 to 2025.
- This data is from Acrivon Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Acrivon Therapeutics, Inc.'s Net Income Loss has declined by 379.6%.
- Historical annual values: Fiscal year 2025: -$77.91 million | Fiscal year 2024: -$80.56 million | Fiscal year 2023: -$60.39 million | Fiscal year 2022: -$31.17 million | Fiscal year 2021: -$16.24 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: